Cagrilintide

NN9838 · CagriSema component

Weight LossNot ApprovedPhase IIIResearchSubQ

Popular for:Weight loss, amylin analog, combined with semaglutide

42

Registered Trials

8

Trial Publications

72

PubMed References

Phase III

Evidence Level

Overview

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for weight management. The short version: people usually care about it for weight loss, amylin analog, combined with semaglutide, but the strength of the evidence depends heavily on indication and study type.

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for weight management. Amylin is a hormone co-secreted with insulin from pancreatic beta cells that promotes satiety, slows gastric emptying, and suppresses glucagon secretion.

Cagrilintide is being developed both as a standalone therapy and in combination with semaglutide under the name CagriSema. Phase 2 trials showed 11.8% body weight loss as monotherapy and up to 17.1% when combined with semaglutide, suggesting the combination may exceed the efficacy of either agent alone.

Research Snapshot

What the evidence says

Phase III

Cagrilintide currently shows 42 registered trials from ClinicalTrials.gov, 8 PubMed trial publications (8 RCT-tagged), and 72 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.

Known vs uncertain

Known signals

  • 42 registered trials are tracked from ClinicalTrials.gov intervention records.
  • 8 PubMed clinical-trial publications are indexed.
  • 8 PubMed randomized controlled trial publications are indexed.
  • 72 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.

Open questions

  • Evidence strength may vary by indication, route, formulation, and population.
  • Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
  • Regulatory status and compounding access can change independently from the research literature.

Mechanism of Action

Cagrilintide is an acylated analog of human amylin that binds to amylin receptors (AMY1 and AMY3) in the area postrema and other brain regions involved in appetite regulation.

Key Research Benefits

Novel amylin-based mechanism distinct from GLP-1 alone
11.8% weight loss as monotherapy in Phase 2
Up to 17.1% combined with semaglutide (CagriSema)
Weekly dosing convenience
Additive effects with GLP-1 agonists on different pathways

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

42

Registered Trials

8

Trial Publications

8

RCT Publications

72

PubMed References

ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026

Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.

42

Registered trials

8

Trial publications

8

RCT publications

72

PubMed references

36

Reviews

3

Meta-analyses

Registered trials source

Jun 1, 2026

Cagrilintide

Uses the exact compound name as a ClinicalTrials.gov intervention query.

View source

Publication counts source

May 3, 2026

Cagrilintide

Uses the exact display name.

View source

Not yet FDA-approved. In Phase 3 clinical trials. CagriSema (cagrilintide + semaglutide) is Novo Nordisk's next-generation weight loss combination. Expected regulatory submission timeline TBD.

Key PubMed References

72 PubMed references · showing top 25 by relevance

View all on PubMed

Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.

Review

Gu YM, Yuan QN, Li X, et al. · Acta pharmacologica Sinica · 2026

PMID: 40847076

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Review

Son JW, le Roux CW, Blüher M, et al. · Endocrine reviews · 2026

PMID: 41054801

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.

Review

Madsbad S, Holst JJ · Expert opinion on investigational drugs · 2025

PMID: 40022548

In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.

Review

Agarwal A, Padwal R · Annals of internal medicine · 2025

PMID: 41052437

Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.

Human Study

Cao J, Belousoff MJ, Johnson RM, et al. · Nature communications · 2025

PMID: 40204768

Anecdotes & Sentiment

Public discussion, not clinical evidence

This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.

mixedAnecdotalApr 28, 2026

CagriSema comparison demand

Cagrilintide is mostly discussed through the CagriSema lens, with users comparing amylin-plus-GLP-1 strategies against tirzepatide.

Reddit / r/GLP1ResearchTalklow confidencereddit
Source

Side Effects & Safety

- Nausea (dose-dependent) - Injection site reactions - GI side effects (diarrhea, constipation) - Still in clinical trials — full safety profile not established

Nausea (dose-dependent)
Injection site reactions
GI side effects (diarrhea, constipation)
Still in clinical trials — full safety profile not established

Known Interactions

No curated interaction entry is live for Cagrilintide yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Comparison Pages

Comparison pages

All

No comparison page is linked yet.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.